KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-cash Items (2018 - 2021)

Historic Non-cash Items for Aquestive Therapeutics (AQST) over the last 4 years, with Q1 2021 value amounting to $6.7 million.

  • Aquestive Therapeutics' Non-cash Items rose 90660.66% to $6.7 million in Q1 2021 from the same period last year, while for Mar 2021 it was $6.7 million, marking a year-over-year increase of 90660.66%. This contributed to the annual value of $1.2 million for FY2020, which is 20569.31% up from last year.
  • According to the latest figures from Q1 2021, Aquestive Therapeutics' Non-cash Items is $6.7 million, which was up 90660.66% from $1.2 million recorded in Q4 2020.
  • Aquestive Therapeutics' 5-year Non-cash Items high stood at $11.4 million for Q2 2019, and its period low was $87000.0 during Q4 2018.
  • Moreover, its 4-year median value for Non-cash Items was $840000.0 (2020), whereas its average is $3.0 million.
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 2799.51% in 2020, then skyrocketed by 90660.66% in 2021.
  • Aquestive Therapeutics' Non-cash Items (Quarter) stood at $87000.0 in 2018, then soared by 364.37% to $404000.0 in 2019, then skyrocketed by 205.69% to $1.2 million in 2020, then surged by 442.83% to $6.7 million in 2021.
  • Its Non-cash Items stands at $6.7 million for Q1 2021, versus $1.2 million for Q4 2020 and $1.0 million for Q3 2020.